<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Tookes HE</submitter><funding>NIDA NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>NIMH NIH HHS</funding><funding>National Cancer Institute</funding><funding>NCI NIH HHS</funding><funding>National Institute of Mental Health</funding><funding>National Institutes of Health</funding><funding>National Institute on Drug Abuse</funding><funding>Miami Center for Aids Research</funding><pagination>109124</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9102418</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>229(Pt A)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>People who inject drugs (PWID) have been a marginalized and a stigmatized population since the beginning of the AIDS epidemic and have not experienced the same life-changing benefits of antiretroviral therapy as others. Tele-Harm Reduction (THR) is a telehealth-enhanced, harm reduction intervention, delivered within a trusted SSP venue. It aims to facilitate initiation of care and achieve rapid HIV viral suppression among PWID living with HIV.&lt;h4>Methods&lt;/h4>In this mixed-methods study, we employed the Practical, Robust, Implementation and Sustainability Model (PRISM) implementation science framework to identify multilevel barriers and facilitators to implementing the THR intervention. Focus groups (n = 2, 16 participants), stakeholder interviews (n = 7) and in-depth int</pubmed_abstract><journal>Drug and alcohol dependence</journal><pubmed_title>Acceptability, feasibility, and pilot results of the tele-harm reduction intervention for rapid initiation of antiretrovirals among people who inject drugs.</pubmed_title><pmcid>PMC9102418</pmcid><funding_grant_id>DP2 DA053720</funding_grant_id><funding_grant_id>P30 AI073961</funding_grant_id><funding_grant_id>P30CA240139</funding_grant_id><funding_grant_id>P30AI073961</funding_grant_id><funding_grant_id>P30 CA240139</funding_grant_id><funding_grant_id>1 DP2 DA053720–01</funding_grant_id><funding_grant_id>3P30MH116867–01A1S1</funding_grant_id><funding_grant_id>R01 DA045713</funding_grant_id><funding_grant_id>P30 MH116867</funding_grant_id><funding_grant_id>UG1 DA013720</funding_grant_id><pubmed_authors>Bartholomew TS</pubmed_authors><pubmed_authors>Kolber MA</pubmed_authors><pubmed_authors>Sternberg C</pubmed_authors><pubmed_authors>Forrest DW</pubmed_authors><pubmed_authors>Boyd D</pubmed_authors><pubmed_authors>Rodriguez A</pubmed_authors><pubmed_authors>Mooss A</pubmed_authors><pubmed_authors>Metsch LR</pubmed_authors><pubmed_authors>Serota DP</pubmed_authors><pubmed_authors>Suarez E</pubmed_authors><pubmed_authors>Ginoza M</pubmed_authors><pubmed_authors>Tookes HE</pubmed_authors><pubmed_authors>Ekowo E</pubmed_authors><pubmed_authors>Feaster DJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Acceptability, feasibility, and pilot results of the tele-harm reduction intervention for rapid initiation of antiretrovirals among people who inject drugs.</name><description>&lt;h4>Background&lt;/h4>People who inject drugs (PWID) have been a marginalized and a stigmatized population since the beginning of the AIDS epidemic and have not experienced the same life-changing benefits of antiretroviral therapy as others. Tele-Harm Reduction (THR) is a telehealth-enhanced, harm reduction intervention, delivered within a trusted SSP venue. It aims to facilitate initiation of care and achieve rapid HIV viral suppression among PWID living with HIV.&lt;h4>Methods&lt;/h4>In this mixed-methods study, we employed the Practical, Robust, Implementation and Sustainability Model (PRISM) implementation science framework to identify multilevel barriers and facilitators to implementing the THR intervention. Focus groups (n = 2, 16 participants), stakeholder interviews (n = 7) and in-depth int</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Dec</publication><modification>2026-06-04T04:41:09.034Z</modification><creation>2025-04-04T19:37:50.968Z</creation></dates><accession>S-EPMC9102418</accession><cross_references><pubmed>34781096</pubmed><doi>10.1016/j.drugalcdep.2021.109124</doi></cross_references></HashMap>